MCID: LMN006
MIFTS: 38

Luminal Breast Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Luminal Breast Carcinoma

MalaCards integrated aliases for Luminal Breast Carcinoma:

Name: Luminal Breast Carcinoma 12 15
Breast Tumor Luminal 12 17
Luminal Breast Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060548

Summaries for Luminal Breast Carcinoma

MalaCards based summary : Luminal Breast Carcinoma, also known as breast tumor luminal, is related to breast ductal carcinoma and in situ carcinoma. An important gene associated with Luminal Breast Carcinoma is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are Pathways in cancer and Development HGF signaling pathway. The drugs Letrozole and Vitamin D have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and testes, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Luminal Breast Carcinoma

Diseases related to Luminal Breast Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 breast ductal carcinoma 30.7 PGR ESR1 ERBB2
2 in situ carcinoma 30.1 PGR KRT5 ESR1 ERBB2
3 breast adenocarcinoma 29.7 PIK3CA ESR1 ERBB2 AKT1
4 ductal carcinoma in situ 29.4 PGR KRT5 ESR1 ERBB2 AKT1
5 estrogen-receptor positive breast cancer 29.1 PIK3CA PGR MTOR FOXA1 ESR1 ERBB2
6 breast cancer 26.5 ZNF703 PIK3CA PGR MTOR KRT5 GATA3
7 bartholin's gland adenoma 10.7 PGR ESR1
8 vestibular gland benign neoplasm 10.7 PGR ESR1
9 lung leiomyoma 10.7 PGR ESR1
10 vulvar syringoma 10.7 PGR ESR1
11 breast apocrine carcinoma 10.7 PGR ERBB2
12 scirrhous adenocarcinoma 10.7 PGR ERBB2
13 vulvar leiomyoma 10.7 PGR ESR1
14 trigonitis 10.6 PGR ESR1
15 vulvar benign neoplasm 10.6 PGR ESR1
16 comedo carcinoma 10.6 ESR1 ERBB2
17 intracystic papillary adenoma 10.6 PGR ERBB2
18 predominantly cortical thymoma 10.6 PGR ESR1
19 oncocytic breast carcinoma 10.6 PGR ESR1
20 bartholin's gland benign neoplasm 10.6 PGR ESR1
21 progesterone-receptor negative breast cancer 10.6 PGR ERBB2
22 endometrial squamous cell carcinoma 10.6 PGR ESR1
23 progesterone resistance 10.6 PGR ESR1
24 adenoid basal cell carcinoma 10.6 PGR ESR1
25 endometrial mucinous adenocarcinoma 10.5 PGR ESR1
26 dermatosis papulosa nigra 10.5 PIK3CA MTOR
27 breast cystic hypersecretory carcinoma 10.5 KRT5 ERBB2
28 synchronous bilateral breast carcinoma 10.5 PGR ESR1
29 diffuse peritoneal leiomyomatosis 10.5 PGR ESR1
30 deep angioma 10.5 PGR ESR1
31 large cell acanthoma 10.5 MTOR KRT5
32 gender identity disorder 10.5 PGR ESR1
33 peritoneal benign neoplasm 10.5 PGR ESR1
34 pancreatic neuroendocrine tumor 10.5 PIK3CA MTOR
35 inverted transitional papilloma 10.5 KRT5 GATA3
36 glassy cell carcinoma of the cervix 10.5 PGR ESR1 ERBB2
37 angiomyolipoma 10.5 PGR MTOR ESR1
38 breast scirrhous carcinoma 10.5 PGR ESR1 ERBB2
39 breast medullary carcinoma 10.5 PGR ESR1 ERBB2
40 progesterone-receptor positive breast cancer 10.5 PGR ESR1 ERBB2
41 cervical carcinosarcoma 10.5 PGR ESR1
42 breast adenoid cystic carcinoma 10.5 PGR ESR1 ERBB2
43 inflammatory breast carcinoma 10.4 PGR ESR1 ERBB2
44 lymphangioleiomyomatosis 10.4 PGR MTOR ESR1
45 mammary paget's disease 10.4 PGR ESR1 ERBB2
46 tubular adenocarcinoma 10.4 PGR ESR1 ERBB2
47 fallopian tube carcinoma 10.4 PGR ESR1 ERBB2
48 female reproductive endometrioid cancer 10.4 PGR ESR1
49 breast fibroadenoma 10.4 PGR ESR1 ERBB2
50 uterine corpus serous adenocarcinoma 10.4 PIK3CA ERBB2

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma:



Diseases related to Luminal Breast Carcinoma

Symptoms & Phenotypes for Luminal Breast Carcinoma

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.68 MTOR PIK3CA
2 Decreased viability GR00221-A-1 9.68 AKT1 ESR1 MTOR PIK3CA
3 Decreased viability GR00221-A-2 9.68 AKT1 ESR1 PIK3CA
4 Decreased viability GR00221-A-3 9.68 AKT1 ERBB2
5 Decreased viability GR00221-A-4 9.68 AKT1 ERBB2 ESR1 MTOR PIK3CA
6 Decreased viability GR00342-S-1 9.68 MTOR
7 Decreased viability GR00342-S-2 9.68 MTOR
8 Decreased viability GR00402-S-2 9.68 AKT1 ERBB2 ESR1 MTOR PIK3CA

MGI Mouse Phenotypes related to Luminal Breast Carcinoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.28 AKT1 CD44 ERBB2 ESR1 GATA3 HORMAD1
2 growth/size/body region MP:0005378 10.24 AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
3 homeostasis/metabolism MP:0005376 10.22 AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
4 behavior/neurological MP:0005386 10.21 AKT1 CD44 ERBB2 ESR1 KRT5 MTOR
5 endocrine/exocrine gland MP:0005379 10.21 AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
6 immune system MP:0005387 10.16 AKT1 CD44 ESR1 FOXA1 GATA3 KDM4C
7 cardiovascular system MP:0005385 10.15 AKT1 CD44 ERBB2 ESR1 GATA3 MTOR
8 mortality/aging MP:0010768 10.14 AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
9 embryo MP:0005380 10.13 AKT1 ERBB2 ESR1 GATA3 HORMAD1 MTOR
10 integument MP:0010771 10.09 AKT1 CD44 ERBB2 ESR1 FOXA1 GATA3
11 muscle MP:0005369 9.97 AKT1 CD44 ERBB2 ESR1 GATA3 MTOR
12 neoplasm MP:0002006 9.92 AKT1 CD44 ERBB2 ESR1 FOXA1 KDM4C
13 no phenotypic analysis MP:0003012 9.8 ESR1 GATA3 KDM4C KRT5 MTOR PGR
14 normal MP:0002873 9.7 AKT1 CD44 ERBB2 ESR1 GATA3 MTOR
15 reproductive system MP:0005389 9.56 AKT1 CD44 ERBB2 ESR1 GATA3 HORMAD1
16 skeleton MP:0005390 9.23 AKT1 CD44 ERBB2 ESR1 GATA3 MTOR

Drugs & Therapeutics for Luminal Breast Carcinoma

Drugs for Luminal Breast Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
2
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
3
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
4 Estrogens Phase 4
5 Hormones Phase 4
6 Steroid Synthesis Inhibitors Phase 4
7 Hormone Antagonists Phase 4
8 Estrogen Receptor Antagonists Phase 4
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
10 Aromatase Inhibitors Phase 4
11 Estrogen Antagonists Phase 4
12 Calcium, Dietary Phase 4
13 Calciferol Phase 4
14
Palbociclib Approved, Investigational Phase 3 571190-30-2 5330286 11431660 5005498
15
Goserelin Approved Phase 3 65807-02-5, 1233494-97-7 47725 5311128
16
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
17 Protein Kinase Inhibitors Phase 3
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Tamoxifen Approved Phase 2 10540-29-1 2733526
20
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
21
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
22
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
23
Lenvatinib Approved, Investigational Phase 2 417716-92-8
24
Phenobarbital Approved, Investigational Phase 2 50-06-6 4763
25
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
26
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
27
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
28
Epirubicin Approved Phase 2 56420-45-2 41867
29
Liposomal doxorubicin Phase 2 31703
30 Selective Estrogen Receptor Modulators Phase 2
31 Estrogen Receptor Modulators Phase 2
32 Bone Density Conservation Agents Phase 2
33 taxane Phase 2
34 Cytochrome P-450 CYP3A Inducers Phase 2
35 Neurotransmitter Agents Phase 2
36 Antineoplastic Agents, Phytogenic Phase 2
37 Central Nervous System Depressants Phase 2
38 GABA Agents Phase 2
39 Cytochrome P-450 Enzyme Inducers Phase 2
40 Albumin-Bound Paclitaxel Phase 2
41 Tubulin Modulators Phase 2
42 Hypnotics and Sedatives Phase 2
43 GABA Modulators Phase 2
44 Excitatory Amino Acid Antagonists Phase 2
45 Anticonvulsants Phase 2
46 Excitatory Amino Acids Phase 2
47 Antimitotic Agents Phase 2
48 Alkylating Agents Phase 2
49 Immunologic Factors Phase 2
50 Anti-Bacterial Agents Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Hormone Therapy Initiation Immediately After Histological Diagnosis of Breast Cancer, Can it Make Any Difference? Not yet recruiting NCT03111615 Phase 4 Aromatase Inhibitors
2 Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant® Recruiting NCT03447132 Phase 3 Fulvestrant 500mg;Palbociclib 125mg;Goserelin 3.6 MG;Placebos
3 A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy. Unknown status NCT02506556 Phase 2 BYl719
4 Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor Unknown status NCT02562118 Phase 1, Phase 2 Lenvatinib + Letrozole
5 Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. Recruiting NCT03283384 Phase 2 Letrozole;Chemotherapy;Ribociclib plus letrozole
6 Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer Recruiting NCT04023292 Phase 2 Endocrine therapy;Endocrine therapy
7 Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer. Recruiting NCT03227328 Phase 2 concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy;chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
8 A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer Recruiting NCT03168074 Phase 2 lenvatinib
9 Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer Active, not recruiting NCT01565499 Phase 2 Nab-paclitaxel
10 Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women Active, not recruiting NCT02400567 Phase 2 Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
11 Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients Recruiting NCT03370250
12 Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Impact of Drug Adherence/Persistence on Clinical Outcome in Various Breast Cancer Subtypes Not yet recruiting NCT03761420

Search NIH Clinical Center for Luminal Breast Carcinoma

Genetic Tests for Luminal Breast Carcinoma

Anatomical Context for Luminal Breast Carcinoma

MalaCards organs/tissues related to Luminal Breast Carcinoma:

41
Breast, Bone, Testes

Publications for Luminal Breast Carcinoma

Articles related to Luminal Breast Carcinoma:

(show all 14)
# Title Authors PMID Year
1
DDR1 and MT1-MMP Expression Levels Are Determinant for Triggering BIK-Mediated Apoptosis by 3D Type I Collagen Matrix in Invasive Basal-Like Breast Carcinoma Cells. 38
31130862 2019
2
First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. 38
29715116 2018
3
Age-related modifications of type I collagen impair DDR1-induced apoptosis in non-invasive breast carcinoma cells. 38
29733741 2018
4
Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. 38
28865009 2018
5
Separase is a marker for prognosis and mitotic activity in breast cancer. 38
28859055 2017
6
Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. 38
28739755 2017
7
FBP1 expression is associated with basal-like breast carcinoma. 38
28529559 2017
8
Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma. 38
27511992 2016
9
Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer. 38
25879784 2015
10
TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. 38
24469049 2015
11
p-mTOR expression is associated with better prognosis in luminal breast carcinoma. 38
25053543 2014
12
Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas. 38
24143191 2013
13
Her2 negative luminal breast carcinoma and Ki-67 evaluation. 38
22647834 2012
14
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. 38
22002565 2012

Variations for Luminal Breast Carcinoma

Expression for Luminal Breast Carcinoma

Search GEO for disease gene expression data for Luminal Breast Carcinoma.

Pathways for Luminal Breast Carcinoma

Pathways related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1 12.74 PIK3CA MTOR ESR1 ERBB2 AKT1
2
Show member pathways
12.59 PIK3CA MTOR ESR1 ERBB2 AKT1
3
Show member pathways
12.57 PIK3CA MTOR ESR1 ERBB2 AKT1
4
Show member pathways
12.53 PIK3CA MTOR ERBB2 AKT1
5 12.47 PIK3CA MTOR ERBB2 CD44
6
Show member pathways
12.44 PIK3CA MTOR ERBB2 AKT1
7
Show member pathways
12.4 PIK3CA PGR MTOR ESR1 ERBB2 AKT1
8
Show member pathways
12.38 PIK3CA MTOR ERBB2 AKT1
9
Show member pathways
12.32 PIK3CA ESR1 CD44 AKT1
10
Show member pathways
12.31 PIK3CA MTOR GATA3 AKT1
11
Show member pathways
12.21 PIK3CA ESR1 ERBB2 AKT1
12
Show member pathways
12.15 PIK3CA MTOR ERBB2 AKT1
13 12.02 PIK3CA MTOR AKT1
14 12.02 PIK3CA MTOR ERBB2 AKT1
15
Show member pathways
12 PIK3CA MTOR ERBB2 AKT1
16
Show member pathways
11.96 PIK3CA ERBB2 AKT1
17 11.93 PIK3CA ERBB2 AKT1
18
Show member pathways
11.9 PIK3CA MTOR AKT1
19
Show member pathways
11.88 PIK3CA MTOR ESR1 ERBB2 ELF5 AKT1
20 11.87 PIK3CA MTOR AKT1
21
Show member pathways
11.84 PIK3CA MTOR AKT1
22 11.84 MTOR ESR1 AKT1
23 11.83 PIK3CA MTOR ESR1 AKT1
24 11.82 PIK3CA MTOR AKT1
25 11.76 KRT5 GATA3 AKT1
26
Show member pathways
11.74 PIK3CA PGR ESR1 ERBB2
27 11.71 GATA3 ESR1 AKT1
28 11.7 PIK3CA MTOR AKT1
29 11.68 PIK3CA MTOR AKT1
30 11.68 PIK3CA ERBB2 AKT1
31 11.66 PIK3CA MTOR ERBB2 AKT1
32 11.63 PIK3CA MTOR AKT1
33
Show member pathways
11.61 PIK3CA MTOR AKT1
34 11.6 MTOR ESR1 AKT1
35 11.59 PIK3CA ERBB2 AKT1
36 11.57 PIK3CA MTOR AKT1
37
Show member pathways
11.56 PIK3CA ERBB2 AKT1
38 11.41 PIK3CA MTOR ESR1 ERBB2 CD44 AKT1
39 11.4 PIK3CA MTOR AKT1
40 11.34 PIK3CA MTOR ERBB2 AKT1
41 11.3 PIK3CA MTOR ERBB2 AKT1
42 11.23 PIK3CA MTOR AKT1
43 11.18 PIK3CA ERBB2 AKT1
44 11.15 PIK3CA MTOR AKT1
45 11.13 MTOR ERBB2 AKT1
46 11.02 PIK3CA ESR1 AKT1
47 10.99 PIK3CA AKT1
48 10.96 PIK3CA AKT1
49 10.96 MTOR AKT1
50 10.91 PIK3CA ESR1 AKT1

GO Terms for Luminal Breast Carcinoma

Cellular components related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.4 ZNF703 PGR MTOR KRT5 KDM4C HORMAD1

Biological processes related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 MTOR KDM4C GATA3 ERBB2 AKT1
2 negative regulation of gene expression GO:0010629 9.76 PGR GATA3 ESR1 AKT1
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.72 FOXA1 ESR1 AKT1
4 chromatin remodeling GO:0006338 9.7 GATA3 FOXA1 ESR1
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.67 PIK3CA CD44 AKT1
6 uterus development GO:0060065 9.59 GATA3 ESR1
7 regulation of myelination GO:0031641 9.58 MTOR AKT1
8 positive regulation of lipid biosynthetic process GO:0046889 9.57 MTOR AKT1
9 TOR signaling GO:0031929 9.54 MTOR GATA3 AKT1
10 negative regulation of macroautophagy GO:0016242 9.5 PIK3CA MTOR AKT1
11 negative regulation of cell size GO:0045792 9.48 MTOR AKT1
12 regulation of glycogen biosynthetic process GO:0005979 9.43 MTOR AKT1
13 mammary gland epithelial cell differentiation GO:0060644 9.43 ZNF703 ELF5 AKT1
14 positive regulation of protein kinase B signaling GO:0051897 9.35 PIK3CA MTOR GATA3 ESR1 ERBB2
15 anoikis GO:0043276 9.33 PIK3CA MTOR AKT1
16 phosphatidylinositol phosphorylation GO:0046854 9.26 PIK3CA
17 positive regulation of transcription by RNA polymerase III GO:0045945 9.21 MTOR
18 phosphatidylinositol 3-kinase signaling GO:0014065 8.92 PIK3CA GATA3 ERBB2 AKT1
19 regulation of transcription by RNA polymerase II GO:0006357 10.06 KDM4C GATA3 FOXA1 ESR1 ERBB2 ELF5
20 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 PGR GATA3 FOXA1 ESR1 ELF5 AKT1

Molecular functions related to Luminal Breast Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.65 PGR GATA3 FOXA1 ESR1 ELF5
2 nitric-oxide synthase regulator activity GO:0030235 9.16 ESR1 AKT1
3 enzyme binding GO:0019899 9.02 PREX1 PGR KDM4C ESR1 AKT1
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.65 PIK3CA

Sources for Luminal Breast Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....